Mehmet Altan, MD
Disclosures: Grant or research support-Bristol-Myers Squibb-|Grant or research support-Eli Lilly and Company-|Grant or research support-F. Hoffmann La Roche Ltd.-|Grant or research support-Genentech, Inc.-|Grant or research support-GlaxoSmithKline-|Grant or research support-Merck and Company, Inc.-|Grant or research support-Novartis AG-|Grant or research support-Nektar therapeutics -|Grant or research support-Jounce Therapeutics-|Grant or research support-Shattuck Labs-|Grant or research support-Adaptimmune-|Membership on advisory committees or review panels, board membership, etc.-GlaxoSmithKline-|Membership on advisory committees or review panels, board membership, etc.-Shattuck Labs- - 04/27/2021

Dr Altan is clinical investigator currently focusing on immunooncology in Thoracic/Head and Neck Cancers. His current research areas include identification of mechanisms for primary and secondary resistance to immunotherapies and predictive markers for immunotherapy toxicities. He also works on translational research projects for identification of spatiotemporal dynamics of the tumor microenvironment in response to immunotherapy to define potential therapeutic targets.